Skin
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Long-Term Survival Outcomes in Advanced Melanoma - Insights From CheckMate 067, KEYNOTE-006, and ImmunoCobiVem Trials
FEATURING
Jessica Hassel
- 12 views
- November 6, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Follow-Up Brain Imaging in Melanoma Patients With Brain Metastasis After ICI
FEATURING
Imren Ozdamar
- 13 views
- November 4, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Neoadjuvant Immunotherapy as the Future of Melanoma Treatment - Identifying Patients Who Need Surgery
FEATURING
Alexander van Akkooi
- 56 views
- October 9, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials
FEATURING
Douglas Johnson
- 178 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Metastatic Melanoma Highlights
FEATURING
Christian Blank
- 197 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Survival Impact of Adjuvant Treatment in Stage III Melanoma
FEATURING
Hildur Helgadottir
- 104 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Distant Metastasis-Free Survival in Neoadjuvant vs. Adjuvant Nivo for Stage III Melanoma - The NADINA Trial
FEATURING
Alexander van Akkooi
- 14 views
- October 22, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Biomarker Analysis and Outcomes in Neoadjuvant Nivo + Relatlimab for Resectable Melanoma
FEATURING
Liz Burton
- 24 views
- October 17, 2024
ecancer
ESMO 2024 Insights: NADINA Trial - Neoadjuvant Ipi Added to Nivo in Resectable Advanced Melanoma
FEATURING
Minke Lucas
- 24 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Sentinel Node (SN) Positive Melanoma With Minimal SN Tumor Burden - Primary Results of the EORTC 1208 Minitub Trial
FEATURING
Alexander van Akkooi
- 28 views
- October 9, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: KEYNOTE-716 - Final Analysis of Distant Metastasis-Free Survival With Adjuvant Pembro vs. Placebo in Resected Stage IIB/IIC Melanoma
FEATURING
Jason Luke
- 23 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Predicting the Outcomes of Advanced Cutaneous Melanoma Cases Following Discontinuation of Immune Checkpoint Inhibition
FEATURING
Ka-Won Noh,
Oana Diana Persa
- 65 views
- October 3, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CFT1946, a Novel BRAF V600X Degrader, in Preliminary Results in BRAF V600 Mutant Solid Tumors
FEATURING
Maria Vieito
- 26 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nivo + Ipi ± ASTX727 in Anti-PD-1 Resistant Metastatic Melanoma - NIBIT-ML1 Ph2 Study
FEATURING
Anna Maria Di Giacomo
- 74 views
- September 20, 2024
- 1